We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Releases Final Guidance for Special Protocol Assessments
FDA Releases Final Guidance for Special Protocol Assessments
The FDA finalized guidance on its special protocol assessment (SPA) program that offers sponsors an advanced declaration from the agency that their trial designs, clinical endpoints, and statistical analyses are acceptable.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor